European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
Standard
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization. / Hübel, K; Fresen, M M; Apperley, J F; Basak, G W; Douglas, K W; Gabriel, I H; Geraldes, C; Jaksic, O; Koristek, Z; Kröger, Nicolaus; Lanza, F; Lemoli, R M; Mikala, G; Selleslag, D; Worel, N; Mohty, M; Duarte, R F.
In: BONE MARROW TRANSPL, Vol. 47, No. 8, 8, 2012, p. 1046-1050.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
AU - Hübel, K
AU - Fresen, M M
AU - Apperley, J F
AU - Basak, G W
AU - Douglas, K W
AU - Gabriel, I H
AU - Geraldes, C
AU - Jaksic, O
AU - Koristek, Z
AU - Kröger, Nicolaus
AU - Lanza, F
AU - Lemoli, R M
AU - Mikala, G
AU - Selleslag, D
AU - Worel, N
AU - Mohty, M
AU - Duarte, R F
PY - 2012
Y1 - 2012
N2 - The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (>2.0 × 10(6) CD34+ cells/kg: 81.6%; >5.0 × 10(6) CD34+ cells/kg: 32.0%) than in NHL patients (>2.0 × 10(6) CD34+ cells/kg: 64.8%; >5.0 × 10(6) CD34+ cells/kg: 12.6%; P2.0 × 10(6) CD34+ cells/kg: 81.5%; >5.0 × 10(6) CD34+ cells/kg: 22.2%) than in NHL patients (P=0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.
AB - The effectiveness of the novel hematopoietic stem cell mobilizing agent plerixafor was evaluated in nationwide compassionate use programs in 13 European countries. A total of 580 poor mobilizers with non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL) and multiple myeloma (MM) were enrolled. All patients received plerixafor plus granulocyte CSF with or without chemotherapy. Overall, the collection yield was significantly higher in MM patients (>2.0 × 10(6) CD34+ cells/kg: 81.6%; >5.0 × 10(6) CD34+ cells/kg: 32.0%) than in NHL patients (>2.0 × 10(6) CD34+ cells/kg: 64.8%; >5.0 × 10(6) CD34+ cells/kg: 12.6%; P2.0 × 10(6) CD34+ cells/kg: 81.5%; >5.0 × 10(6) CD34+ cells/kg: 22.2%) than in NHL patients (P=0.013). In a subgroup analysis, there were no significant differences in mobilization success comparing patients with diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Our data emphasize the role of plerixafor in poor mobilizers, but further strategies to improve the apheresis yield especially in patients with NHL are required.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Child
KW - European Union
KW - Leukocyte Count
KW - Transplantation, Homologous
KW - Anti-HIV Agents/administration & dosage
KW - Hematopoietic Stem Cell Transplantation
KW - Hematopoietic Stem Cell Mobilization/methods
KW - Lymphoma, Non-Hodgkin/blood/therapy
KW - Multiple Myeloma/blood/therapy
KW - Blood Component Removal/methods
KW - Granulocyte Colony-Stimulating Factor
KW - Heterocyclic Compounds/administration & dosage
KW - Hodgkin Disease/blood/therapy
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Adolescent
KW - Child
KW - European Union
KW - Leukocyte Count
KW - Transplantation, Homologous
KW - Anti-HIV Agents/administration & dosage
KW - Hematopoietic Stem Cell Transplantation
KW - Hematopoietic Stem Cell Mobilization/methods
KW - Lymphoma, Non-Hodgkin/blood/therapy
KW - Multiple Myeloma/blood/therapy
KW - Blood Component Removal/methods
KW - Granulocyte Colony-Stimulating Factor
KW - Heterocyclic Compounds/administration & dosage
KW - Hodgkin Disease/blood/therapy
M3 - SCORING: Journal article
VL - 47
SP - 1046
EP - 1050
JO - BONE MARROW TRANSPL
JF - BONE MARROW TRANSPL
SN - 0268-3369
IS - 8
M1 - 8
ER -
